The smaller company believes that its complement C3 inhibitor could make Soliris and Ultomiris redundant in PNH.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.
The study marks victory against Soliris, but Apellis could still find the market hard to crack.
Biomarin awaits pivotal data on one of its growth drivers, while Apellis seeks to take off on Pegasus.